ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2016
Methylation of ASC/TMS1 promoter is associated with poor prognosis of patients with gastric cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- From mechanisms to markers: role of pyroptosis in revolutionizing thyroid cancer care.Cell death discovery · 2025Review
- Aberrant DNA methylation as a key modulator of cell death pathways: insights into cancer progression and other diseases.Functional & integrative genomics · 2025Review
- Identification of PANoptosis-related genes as prognostic indicators of thyroid cancer.Heliyon · 2024Article
- NLRP3: a new therapeutic target in alcoholic liver disease.Frontiers in immunology · 2023Review
- Article
- An Epigenetic Insight into NLRP3 Inflammasome Activation in Inflammation-Related Processes.Biomedicines · 2021Review
- High expression of PYCARD is an independent predictor of unfavorable prognosis and chemotherapy resistance in glioma.Annals of translational medicine · 2021Article
- Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia.Scientific reports · 2021Article
- Dual Role of Inflammasome Adaptor ASC in Cancer.Frontiers in cell and developmental biology · 2020Review
- Promoter methylation status ofTranslational lung cancer research · 2019Article
- Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array.Clinical epigenetics · 2019Article
- The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer.Journal for immunotherapy of cancer · 2019Article
- Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.Seminars in cancer biology · 2018Review
- The contrasting roles of inflammasomes in cancer.American journal of cancer research · 2018Review
- The PYHIN Protein p205 Regulates the Inflammasome by Controlling Asc Expression.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1, CLIP4 and MSC DNA methylation in endoscopic biopsies.Oncotarget · 2017Article
- Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development.Frontiers in immunology · 2017Review
- Novel role of ASC as a regulator of metastatic phenotype.Cancer medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was conducted to explore the prognostic value of the methylation status of the ASC/TMS1 (apoptosis-associated speck-like protein containing a CARD/the target of methylation-induced silencing-1) promoter in gastric cancer (GC).
methodsASC/TMS1 expression was detected in GC tissues and normal gastric mucosal tissues by real-time quantitative PCR and Western blot analysis. Methylation-specific PCR (MSP) analysis was performed to detect the methylated degrees of the DNA of the ASC/TMS1 promoter of 200 GC patients. Associations between molecular, clinicopathological characteristics and survival data were analyzed.
resultsThe mRNA and protein expression levels of ASC/TMS1 in GC tissues were lower than those in normal gastric mucosal tissues. With the MSP detection, ASC/TMS1 promoter methylation was found in 68 (34 %) in 200 GC tissues, while none of 40 normal gastric mucosal tissues were found to be methylated. The size of primary tumor and lymph node metastasis were identified as independent relative factors of methylation status of the ASC/TMS1 promoter in GC tissues. Multivariate analysis results demonstrated that the degree of differentiation, serosal invasion, lymph node metastasis and methylated status of ASC/TMS1 promoter were independent prognostic indicators of GC. Lymph node metastasis and methylated status of ASC/TMS1 promoter were optimal prognostic predictors of GC patients, as identified by Cox regression with Akaike information criterion value calculation.
conclusionsThe methylated status of ASC/TMS1 promoter had the potential applicability for clinical evaluation the prognosis of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.